We are thrilled to announce that Explicyte will be attending the AACR annual meeting this year in Orlando, to share our latest developments and translational research works.
A new anti-PD1 resistant mouse sarcoma model, ovarian cancer ascites as a remarkable tool for translational research or our GeoMx platform to support your spatial transcriptomics programs... check out our best highlights of 2022!
We very much look forward to attending the @Society for Immunotherapy of Cancer Annual Meeting in Boston from November 8 to 12, and to showcasing our recent research works through our posters. Plan to stop by to talk of them and about your research programs.
Discover our main news for the first half of 2022! Hear about the great opportunity that is our partnership with Domain Therapeutics, new cutting-edge platforms for biomarker translational research as well as our newest featured publication!
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
In the era of immuno-oncology, it’s critical to unravel mechanisms of action underlying sensitivity or resistance to current immunotherapies in order to identify predictive biomarkers of response and then discover novel actionable therapeutic targets.
We will be attending the AACR Annual Meeting in New Orleans, from April 8 to 13, 2022. We will be glad to take this opportunity to meet you there!
Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), and Explicyte, an expert in the field of IO and innovative target identification through multiparametric approaches, announce today the signing of a partnership agreement.
Explicyte will be attending the AACR Virtual Annual Meeting 2020 and will present new results from its collaborative work with Domain Therapeutics on the GPCRome modulation in the context of cancer immunotherapy.
Anti-angiogenic therapy combination with hypoxia-regulating agent leads to improved tumor regression
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
We will be attending the AACR Virtual Annual Meeting, from June 22 to 24, 2020 to present our posters featuring our capacities / platforms that support drug discovery in Immuno-Oncology.
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.